Personal information

No personal information available

Activities

Collapse all

Employment (10)

University of Oxford: Oxford, Oxfordshire, GB

2010-10-01 to present | Professor of Cancer Medicine (NDCLS)
Employment
Source: Self-asserted source
David Kerr

Oxford University Hospitals NHS Trust: Oxford, Oxfordshire, GB

2010-10-01 to present | Consultant Physician
Employment
Source: Self-asserted source
David Kerr

University of Strathclyde: Glasgow, Glasgow, GB

1990-07-01 to present | Honorary Professor (Pharmacology)
Employment
Source: Self-asserted source
David Kerr

Sidra Medical and Research Center: Doha, Ad Dawhah, QA

2009-03-01 to 2010-10-01 | Chief Research Adviser
Employment
Source: Self-asserted source
David Kerr

University of Oxford: Oxford, Oxfordshire, GB

2001-10-01 to 2009-03-31 | Department Head (Clinical Pharmacology)
Employment
Source: Self-asserted source
David Kerr

University of Oxford: Oxford, Oxfordshire, GB

2001-10-01 to 2006-04-30 | Director (NTRAC)
Employment
Source: Self-asserted source
David Kerr

University of Birmingham: Birmingham, Birmingham, GB

1992-03-01 to 2001-09-30 | Clinical Oncology (Professor)
Employment
Source: Self-asserted source
David Kerr

Queen Elizabeth Hospital Birmingham: Birmingham, Birmingham, GB

1992-03-01 to 2001-09-30 | Consultant Physician (Birmingham Oncology centre)
Employment
Source: Self-asserted source
David Kerr

University of Glasgow: Glasgow, Glasgow, GB

1989-07-01 to 1992-02-28 | Senior Lecturer (Medical Oncology)
Employment
Source: Self-asserted source
David Kerr

University of Glasgow: Glasgow, Glasgow, GB

1984-04-01 to 1988-09-31 | Senior Registrar (Medical Oncology)
Employment
Source: Self-asserted source
David Kerr

Education and qualifications (3)

University of Oxford: Oxford, Oxfordshire, GB

2001-09-01 to 2002-07-31 | MA
Education
Source: Self-asserted source
David Kerr

University of Glasgow: Glasgow, Glasgow, GB

1986-09-01 to 1990-07-01 | PhD
Education
Source: Self-asserted source
David Kerr

University of Glasgow: Glasgow, Glasgow, GB

1976-09-01 to 1980-07-31 | MBChB
Education
Source: Self-asserted source
David Kerr

Funding (6)

Investigation of biomarkers of response to the specific COX-2 inhibitor rofecoxib (VioxxTM) in colorectal cancer patients

Source: Self-asserted source
David Kerr via DimensionsWizard

SCOT- Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal ca by the CACTUS & QUASAR 3 Groups.

Source: Self-asserted source
David Kerr via DimensionsWizard

Germline variation in DNA repair genes as determinants of presenting features and outcome in bowel cancer patients from

Source: Self-asserted source
David Kerr via DimensionsWizard

Identification and structural characterisation of molecular markers of colorectal cancer

Source: Self-asserted source
David Kerr via DimensionsWizard

CRUKE/02/017*: QUASAR II: Adjuvant chemotherapy trial in colorectal cancer

2002-06-01 to 2008-05-31 | Grant
Cancer Research UK (n/a, GB)
URL: https://grants.uberresearch.com/501100000289/CRUK-A4069/CRUKE-02-017-QUASAR-II-Adjuvant-chemotherapy-trial-in-colorectal-cancer
GRANT_NUMBER:

grant.CRUK-A4069
Source: Self-asserted source
David Kerr via DimensionsWizard

Targeting Cancer Chemotherapy : For the Control of Metastatic Liver Cancer

1996-01-01 to 1998-12-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://grants.uberresearch.com/501100001691/08045067/Targeting-Cancer-Chemotherapy-For-the-Control-of-Metastatic-Liver-Cancer
GRANT_NUMBER: grant.08045067
Source: Self-asserted source
David Kerr via DimensionsWizard

Works (50 of 54)

Items per page:
Page 1 of 2

Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Molecular Cancer Research
2025-01-22 | Journal article
DOI: 10.1158/1541-7786.MCR-24-0464
Contributors: Connor E. Woolley; Enric Domingo; Juan Fernandez-Tajes; Kathryn A.F. Pennel; Patricia Roxburgh; Joanne Edwards; Susan D. Richman; Tim S. Maughan; David J. Kerr; Ignacio Soriano et al.
Source: check_circle
Crossref

Bestrophin-4 relays Hes4 and interacts with Twist1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells

2024-10-04 | Preprint
DOI: 10.7554/eLife.88879
Contributors: Zijing Wang; Bihan Xia; Shaochong Qi; Xian Zhang; Xiaoshuang Zhang; Yan Li; Huimin Wang; Miao Zhang; Ziyi Zhao; David Kerr et al.
Source: check_circle
Crossref

Bestrophin-4 relays Hes4 and interacts with Twist1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells

2024-10-04 | Preprint
DOI: 10.7554/eLife.88879.2
Contributors: Zijing Wang; Bihan Xia; Shaochong Qi; Xian Zhang; Xiaoshuang Zhang; Yan Li; Huimin Wang; Miao Zhang; Ziyi Zhao; David Kerr et al.
Source: check_circle
Crossref

Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit

JCO Global Oncology
2024-05 | Journal article
DOI: 10.1200/GO.23.00256
Contributors: Edward Briercheck; Doug Pyle; Cary Adams; Rifat Atun; Christopher Booth; Jennifer Dent; Pat Garcia-Gonzalez; Andre Ilbawi; Abdul Rahman Jazieh; David Kerr et al.
Source: check_circle
Crossref

An Explainable Coarse-to-Fine Survival Analysis Method on Multi-Center Whole Slide Images

IEEE Transactions on Artificial Intelligence
2024-03 | Journal article
DOI: 10.1109/TAI.2023.3285855
Contributors: Han Wang; Dan Jiang; Haixian Zhang; Yujue Wang; Li Yang; David J. Kerr; Yi Zhang
Source: check_circle
Crossref

Personalizing adjuvant therapy for patients with colorectal cancer

Nature Reviews Clinical Oncology
2024-01 | Journal article
DOI: 10.1038/s41571-023-00834-2
Contributors: Li Yang; Jinlin Yang; Andreas Kleppe; Håvard E. Danielsen; David J. Kerr
Source: check_circle
Crossref

Bestrophin-4 relays Hes4 and interacts with Twist1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells

2023-11-01 | Preprint
DOI: 10.7554/eLife.88879.1
Contributors: Zijing Wang; Bihan Xia; Shaochong Qi; Xian Zhang; Xiaoshuang Zhang; Yan Li; Huimin Wang; Miao Zhang; Ziyi Zhao; David Kerr et al.
Source: check_circle
Crossref

Bestrophin-4 relays Hes4 and interacts with Twist1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells

2023-07-03 | Preprint
DOI: 10.1101/2023.07.03.547525
Contributors: Zijing Wang; Bihan Xia; Shaochong Qi; Xian Zhang; Xiaoshuang Zhang; Yan Li; Huimin Wang; Miao Zhang; Ziyi Zhao; David Kerr et al.
Source: check_circle
Crossref

Personalising cancer medicine with prognostic markers

eBioMedicine
2021-10 | Journal article
DOI: 10.1016/j.ebiom.2021.103577
Contributors: David J Kerr; Li Yang
Source: check_circle
Crossref

Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer

eBioMedicine
2021-09 | Journal article
DOI: 10.1016/j.ebiom.2021.103547
Contributors: Dan Jiang; Tarjei S. Hveem; Mark Glaire; David N. Church; David J. Kerr; Li Yang; Håvard E. Danielsen
Source: check_circle
Crossref

Designing deep learning studies in cancer diagnostics

Nature Reviews Cancer
2021-03-29 | Journal article
DOI: 10.1038/s41568-020-00327-9
Contributors: Andreas Kleppe; Ole-Johan Skrede; Sepp De Raedt; Knut Liestøl; David J. Kerr; Håvard E. Danielsen
Source: check_circle
Crossref

Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019)

European Journal of Surgical Oncology
2020-06 | Journal article
DOI: 10.1016/j.ejso.2020.02.019
Contributors: Li Ren; Dexiang Zhu; Al B. Benson, III; Bernard Nordlinger; Claus-Henning Koehne; Conor P. Delaney; David Kerr; Heinz-Josef Lenz; Jia Fan; Jianping Wang et al.
Source: check_circle
Crossref

The Oncology Data Network (ODN): A Collaborative European Data‐Sharing Platform to Inform Cancer Care

The Oncologist
2020-01-05 | Journal article
DOI: 10.1634/theoncologist.2019-0337
Contributors: David Kerr; Dirk Arnold; Jean‐Yves Blay; Christian Buske; Alfredo Carrato; Winald Gerritsen; Marc Peeters
Source: check_circle
Crossref

Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.

European journal of cancer (Oxford, England : 1990)
2017-10 | Journal article
DOI: 10.1016/j.ejca.2017.07.034
PMID: 28829991
Source: Self-asserted source
David Kerr via Europe PubMed Central

Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.

International journal of cancer
2017-09 | Journal article
DOI: 10.1002/ijc.31076
PMID: 28960316
Source: Self-asserted source
David Kerr via Europe PubMed Central

Intra-tumoural stromal morphometry predicts disease recurrence but not response to 5-fluorouracil - results from the QUASAR trial of colorectal cancer.

Histopathology
2017-07 | Journal article
DOI: 10.1111/his.13326
PMID: 28746977
Source: Self-asserted source
David Kerr via Europe PubMed Central

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.

International journal of cancer
2017-06 | Journal article
DOI: 10.1002/ijc.30709
PMID: 28340513
Source: Self-asserted source
David Kerr via Europe PubMed Central

Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.

Genome medicine
2017-05 | Journal article
DOI: 10.1186/s13073-017-0434-0
PMID: 28539123
PMC: PMC5442873
Source: Self-asserted source
David Kerr via Europe PubMed Central

Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach.

Nature reviews. Clinical oncology
2016-11 | Journal article
DOI: 10.1038/nrclinonc.2016.94
PMID: 27349194
Source: Self-asserted source
David Kerr via Europe PubMed Central

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

The Lancet. Oncology
2016-11 | Journal article
DOI: 10.1016/s1470-2045(16)30172-3
PMID: 27660192
Source: Self-asserted source
David Kerr via Europe PubMed Central

Is sidedness prognostically important across all stages of colorectal cancer?

The Lancet. Oncology
2016-11 | Journal article
DOI: 10.1016/s1470-2045(16)30431-4
PMID: 27819229
Source: Self-asserted source
David Kerr via Europe PubMed Central

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

The lancet. Gastroenterology & hepatology
2016-11 | Journal article
DOI: 10.1016/s2468-1253(16)30014-0
PMID: 28404093
Source: Self-asserted source
David Kerr via Europe PubMed Central

Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.

British journal of cancer
2016-07 | Journal article
DOI: 10.1038/bjc.2016.188
PMID: 27336604
PMC: PMC4947703
Source: Self-asserted source
David Kerr via Europe PubMed Central

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.

Human molecular genetics
2016-06 | Journal article
DOI: 10.1093/hmg/ddw087
PMID: 27005424
PMC: PMC5081051
Source: Self-asserted source
David Kerr via Europe PubMed Central

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2016-04 | Journal article
DOI: 10.1200/jco.2015.65.1158
PMID: 26858337
PMC: PMC4933130
Source: Self-asserted source
David Kerr via Europe PubMed Central

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

The Journal of pathology
2016-03 | Journal article
DOI: 10.1002/path.4679
PMID: 26690310
PMC: PMC4785607
Source: Self-asserted source
David Kerr via Europe PubMed Central

Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer.

Oncoscience
2015 | Journal article
PMID: 26097884
PMC: PMC4468337
Source: Self-asserted source
David Kerr via Europe PubMed Central

Connecting the Global Cancer Community.

Journal of global oncology
2015-12 | Journal article
DOI: 10.1200/jgo.2015.001503
PMID: 28804771
PMC: PMC5539875
Source: Self-asserted source
David Kerr via Europe PubMed Central

Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.

Clinical cancer research : an official journal of the American Association for Cancer Research
2015-08 | Journal article
DOI: 10.1158/1078-0432.ccr-14-3136
PMID: 25873087
PMC: PMC4526710
Source: Self-asserted source
David Kerr via Europe PubMed Central

Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.

Scientific reports
2015-08 | Journal article
DOI: 10.1038/srep12372
PMID: 26237130
PMC: PMC4523102
Source: Self-asserted source
David Kerr via Europe PubMed Central

A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.

Scientific reports
2015-05 | Journal article
DOI: 10.1038/srep10442
PMID: 25990418
PMC: PMC4438486
Source: Self-asserted source
David Kerr via Europe PubMed Central

Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial.

Anticancer research
2015-03 | Journal article
PMID: 25750322
Source: Self-asserted source
David Kerr via Europe PubMed Central

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

Gut
2015-01 | Journal article
DOI: 10.1136/gutjnl-2013-306571
PMID: 24647007
PMC: PMC4283622
Source: Self-asserted source
David Kerr via Europe PubMed Central

Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.

Molecular oncology
2015-01 | Journal article
DOI: 10.1016/j.molonc.2014.07.017
PMID: 25224594
PMC: PMC4286123
Source: Self-asserted source
David Kerr via Europe PubMed Central

Health diplomacy: a new approach to the Muslim world?

Globalization and health
2014 | Journal article
DOI: 10.1186/1744-8603-10-50
PMID: 24927759
PMC: PMC4071330
Source: Self-asserted source
David Kerr via Europe PubMed Central

Clinical cancer research: the past, present and the future.

Nature reviews. Clinical oncology
2014-11 | Journal article
DOI: 10.1038/nrclinonc.2014.153
PMID: 25245981
Source: Self-asserted source
David Kerr via Europe PubMed Central

Policy: EU data protection regulation--harming cancer research.

Nature reviews. Clinical oncology
2014-10 | Journal article
DOI: 10.1038/nrclinonc.2014.148
PMID: 25178633
Source: Self-asserted source
David Kerr via Europe PubMed Central

'Toxgnostics': an unmet need in cancer medicine.

Nature reviews. Cancer
2014-06 | Journal article
DOI: 10.1038/nrc3729
PMID: 24827503
Source: Self-asserted source
David Kerr via Europe PubMed Central

Building capacity for sustainable research programmes for cancer in Africa.

Nature reviews. Clinical oncology
2014-05 | Journal article
DOI: 10.1038/nrclinonc.2014.37
PMID: 24614139
PMC: PMC4403794
Source: Self-asserted source
David Kerr via Europe PubMed Central

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014-04 | Journal article
DOI: 10.1200/jco.2013.51.1857
PMID: 24590654
PMC: PMC4879695
Source: Self-asserted source
David Kerr via Europe PubMed Central

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013-12 | Journal article
DOI: 10.1200/jco.2013.50.0322
PMID: 24062397
Source: Self-asserted source
David Kerr via Europe PubMed Central

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.

The American journal of gastroenterology
2013-11 | Journal article
DOI: 10.1038/ajg.2013.292
PMID: 24042191
Source: Self-asserted source
David Kerr via Europe PubMed Central

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Clinical colorectal cancer
2013-09 | Journal article
DOI: 10.1016/j.clcc.2013.04.004
PMID: 23810482
PMC: PMC3760214
Source: Self-asserted source
David Kerr via Europe PubMed Central

Biological markers: Tailoring treatment and trials to prognosis.

Nature reviews. Clinical oncology
2013-08 | Journal article
DOI: 10.1038/nrclinonc.2013.97
PMID: 23752731
Source: Self-asserted source
David Kerr via Europe PubMed Central

Stage II colon cancer.

Chinese clinical oncology
2013-06 | Journal article
DOI: 10.3978/j.issn.2304-3865.2013.03.03
PMID: 25841496
Source: Self-asserted source
David Kerr via Europe PubMed Central

Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013-04 | Journal article
DOI: 10.1200/jco.2012.47.2852
PMID: 23509312
Source: Self-asserted source
David Kerr via Europe PubMed Central

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.

Nature genetics
2013-02 | Journal article
DOI: 10.1038/ng.2503
PMID: 23263490
PMC: PMC3785128
Source: Self-asserted source
David Kerr via Europe PubMed Central

Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

The Journal of pathology
2013-02 | Journal article
DOI: 10.1002/path.4139
PMID: 23165447
PMC: PMC3588155
Source: Self-asserted source
David Kerr via Europe PubMed Central

The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Annals of oncology : official journal of the European Society for Medical Oncology
2013-01 | Journal article
DOI: 10.1093/annonc/mds246
PMID: 22865778
Source: Self-asserted source
David Kerr via Europe PubMed Central

Biomarkers in early-stage colorectal cancer: ready for prime time?

Digestive diseases (Basel, Switzerland)
2012 | Journal article
DOI: 10.1159/000341890
PMID: 23207929
Source: Self-asserted source
David Kerr via Europe PubMed Central
Items per page:
Page 1 of 2

Peer review (1 review for 1 publication/grant)

Review activity for The lancet oncology. (1)
How many people are using ORCID?